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Abstract 
The underlying mechanisms that allow proinflammatory cytokines to exert a direct 
adverse effect on growth plate chondrogenesis are unclear. These effects may be 
mediated by ceramide, a sphingosine-based lipid second messenger, which is elevated 
in a number of chronic inflammatory diseases.  To test this hypothesis, we determined 
the effects of C2-ceramide a cell permeable ceramide analogue, on the growth of the 
ATDC5 chondrogenic cell line and on cultured fetal mice metatarsals. 
 
In ATDC5 cells, C2-ceramide significantly induced apoptosis at both 40µM (82%; 
P<0.05) and 25µM (53%; P<0.05). At 40µM, C2-ceramide significantly reduced 
proliferation ([3H]-thymidine uptake/mg protein) (62%; P<0.05).  Cell number was 
significantly reduced at both 40µM (72%; P<0.05) and 25µM (62%; P<0.05).  C2-
ceramide did not markedly alter the mRNA expression of markers of chondrogenesis 
(sox 9 and collagen II) and differentiation (aggrecan and collagen X). Both, in the 
presence and absence of IGF-1, C2-ceramide (25µM) induced an equivalent amount 
of reduction (60%) in proliferation (P<0.001).  Similarly, C2-ceramide (40µM) 
induced a 31% reduction in fetal metatarsal growth both in the presence and absence 
of IGF-1 (both P<0.001).  Therefore, C2-ceramide does not appear to specifically 
inhibit the pro-proliferative effects of exogenous IGF-1. AG1024, an IGF-1 and 
insulin receptor blocker, reduced proliferation by 28% compared to control cells 
(P<0.001). C2-ceramide (25µM) significantly reduced proliferation compared to 
AG1024 treatment (55%, P<0.001).  C2-ceramide and AG1024 in combination 
further reduced proliferation compared to C2-ceramide alone (46 %; P<0.01). Cell 
signalling studies demonstrated that C2-ceramide (25µM) treatment for 24h did not 
alter IGF-1-stimulated phosphorylation of IRS-1, Akt or Erk 1/2.  
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In conclusion, C2-ceramide inhibits proliferation and induces apoptosis in growth 
plate chondrocytes through an IGF-1 independent mechanism.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
Introduction 
 
Chronic inflammatory diseases such as Juvenile Idiopathic Arthritis (JIA) and 
Inflammatory Bowel Disease (IBD) often lead to childhood growth retardation 
through a number of proposed mechanisms that includes nutritional deficiency, 
chronic inflammation, increased catabolism, defects in the GH/IGF-1 axis and use of 
glucocorticoids (MacRae et al. 2006a; Wong et al. 2006). Proinflammatory cytokines 
such as TNFα and IL-1β, are often raised in these diseases, and measures that block 
TNFα action such as anti-TNF therapy lead to an improvement in growth, an effect 
which has been reported to be independent of the concurrent reduction in the need for 
therapy with glucocorticoids (Tynjala et al. 2006). TNFα and IL-1β, may directly 
inhibit growth plate chondrocyte dynamics as well as longitudinal growth in vitro 
Martensson et al. 2004; MacRae et al. 2006b) but the underlying mechanisms that 
lead to these effects are unclear.   
 
The insulin-like growth factor–I (IGF-I) signalling pathway is the major 
autocrine/paracrine regulator of bone growth (Loveridge et al. 1990). Binding of IGF-
I to its receptor utilises a family of soluble receptors, known as insulin receptor 
substrates (IRSs), to initiate a series of autophosphorylation events. This results in the 
activation of two distinct signalling pathways, phosphatidylinositol 3-kinase (PI-3K) 
and p44/p42 mitogen-activated protein kinase (MAPK), leading to pro-proliferative 
and anti-apoptotic effects.   
 
In many cell types, signal transduction of IL-1β and TNFα involves the activation of 
neutral (N) and acidic (A) sphingomyelinase (Smase) pathways, which catalyse the 
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degradation of the membrane phospholipid sphingomyelin into phosphocholine and 
ceramide (Mathias et al. 1993; Weigmann et al. 1994; Rybakina et al. 2001).  
Ceramide is also elevated through a de novo synthesis pathway following activation 
of IL-1β and TNFα receptors (Memon et al. 1998; Xu et al. 1998).  Ceramide has 
been shown to inhibit IGF-1-induced tyrosine phosphorylation of IRS-1 in myoblast 
and hepatic cells (Kanety et al. 1996; Strle et al. 2004).  Ceramide has also been 
shown to induce apoptosis in a wide range of different cell types, including pancreatic 
beta cells (Sjoholm et al. 2005), cardiomyocytes (de Vries et al.1997), astrocytes (Oh 
et al. 2006) and articular chondrocytes (Sabatini et al. 2000).  
Whilst previous studies that have shown that IL-1β and TNFα inhibit growth plate 
chondrocyte differentiation and induce cell death (Martensson et al. 2004; MacRae et 
al. 2006b), the direct effects of ceramide on growth plate chondrocytes have yet to be 
reported.  In this study, the ATDC5 chondrogenic cell line was used to characterise 
and compare the effects of ceramide on cell proliferation, differentiation and 
apoptosis. Subsequently, the effect of ceramide on IGF-1 signalling was examined 
using ATDC5 cells and the fetal murine metatarsal model.  
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Materials & Methods 
 
Chondrocyte cell culture 
The ATDC5 chondrocyte cell line was sourced from the RIKEN cell bank (Ibaraki, 
Japan) and maintained as described by Atsumi et al. (1990).  Cells were maintained in 
T175 tissue-culture flasks (Greiner Bio-One GmbH, Frickenhausen, Baden-
Württemberg, Germany) at a density of 250,000 cells/flask in a maintenance medium 
of DMEM/Ham’s F12 (Invitrogen, Paisley, Strathclyde, UK) supplemented with 5% 
FCS (Invitrogen), 10µgml-1 human transferrin, 3 x 10-8M sodium selenite (Sigma, 
Poole, Dorset, UK), sodium pyruvate (1mM; Invitrogen) and gentamycin (50µg/ml 
Invitrogen).  For individual experiments semi-confluent cultures were passaged with 
trypsin-EDTA (Sigma) and cultured (Day 0) at a density of 6,000 cells/cm2 in multi-
well plates (Costar, High Wycombe, Bucks, UK) in a differentiation medium that 
consisted of maintenance medium supplemented with insulin (10µg/ml; Sigma). 
Incubation was at 37°C in a humidified atmosphere of 95% air / 5% CO2 and the 
medium was changed every second / third day.  In all experiments, unless otherwise 
stated, C2-ceramide (Sigma), a cell permeable ceramide analogue, was added to 
chondrocyte cultures on Day 6, at a final concentration of 40, 25 and 10µM. The 
diluent for C2-ceramide was ethanol (final concentration 0.1%).  All control cultures 
received 0.1% ethanol only.   
  
ATDC5 cells were deprived of serum and ITS for 18h before the initiation of 
treatments in the presence of IGF-1 (100ng/ml) (Bachem (UK) Ltd., St. Helens, 
Merseyside, UK), and before the initiation of the cell signalling studies.     
 
 7 
Inhibition of ceramide generation following pro-inflammatory cytokine exposure. 
D609 (10µg/ml), an inhibitor of A-SMase activity, was added to cells cultured in 48 
well plates, in the presence of IL-1β and TNFα (both 10ng/ml).  The rate of 
chondrocyte proliferation was assessed over a 24 hour period starting on Day 6.  On 
Day 7, the chondrocytes were incubated with 0.2µCi/ml [3H]thymidine (37MBq/ml; 
Amersham Pharmacia Biotech, Bucks, UK) for the last 2 hours of the culture period. 
The amount of radioactivity incorporated into trichloroacetic acid-insoluble 
precipitates was measured (Farquharson et al. 1999). 
 
Chondrocyte number, proliferation and apoptosis  
Protein content was determined as a measure of cell number.  Cells were cultured in 
12 well plates, and exposed to C2-ceramide on Day 6 and Day 8.  On Day 10, the 
cells were washed twice with phosphate buffered saline, lysed with 0.9% NaCl and 
0.2% Triton X-100 and centrifuged at 12000g for 15min at 4°C.  The protein content 
of the supernatant was measured using the Bio-Rad protein assay reagent (Bio-Rad 
Laboratories) based on the Bradford dye binding procedure, and gamma globulin as 
standard (Farquharson et al. 1995). Proliferation was determined as described above. 
Apoptosis of the cells was measured using the APO Percentage Apoptosis assay, 
(Biocolor Ltd, Belfast, N Ireland), which quantifies dye uptake by apoptotic cells only 
after the translocation of phosphatidylserine to the outer surface of the cell membrane 
(Fadok et al. 1992). Apoptosis was assessed following the manufacturer’s protocol in 
cells cultured in 48 well plates over a 24-hour period starting on Day 6.   
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Analysis of chondrogenic gene expression 
On days 13 and 15, C2-ceramide was added to cells cultured in 6 well plates. During 
this period the cells express established markers of the chondrocyte differentiated 
phenotype (Mushtaq et al. 2002).  The experiment was stopped on day 17 and total 
RNA was extracted from chondrocytes by repeated aspiration through a 25-gauge 
syringe needle in 0.5ml Ultraspec (Biotecx, Houston, TX, USA).  Following 
extraction with chloroform, RNA in the aqueous phase was precipitated with 
isopropanol and bound to RNA Tack resin (Biotecx) following the manufacturer’s 
protocol.  After washing with 75% ethanol, the RNA was eluted in 100µl ribonuclease 
–free water (Houston et al. 1999).  For each sample, total RNA content was assessed 
by absorbance at 260nm and purity by A260/A280 ratios, which were 1.9-2.0 in all 
cases.  All preparations were diluted to a concentration of 50ng/µl and stored at -
70°C.  Gene expression was analysed by semi-quantitative RT-PCR (Jefferies et al. 
1998; Farquharson et al. 1999; Houston et al. 1999; Jefferies et al. 2000).  Aliquots of 
500ng RNA (or an equivalent volume of water as a control) were reverse transcribed 
in 20µl reactions containing cDNA equivalent to 10ng RNA and 200nM gene-specific 
primers in 11.1 X PCR buffer (Jefferies et al. 2000).  The cycling profile was 1 min at 
92°C (first cycle, 2 min), 1 min at 55°C, and 1 min at 70°C.  The number of cycles 
performed was carefully titrated to ensure that the reactions were in the exponential 
phase.  Reaction products were analysed on 1.5% agarose gels in the presence of 
ethidium bromide (250µg/l), and a digital image of each gel was captured using a gel 
documentation system (Bio-Rad Laboratories, Inc., Hemel Hempstead, Herts, UK). 
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IGF-1 studies  in ATDC5 cells 
The cells were treated with C2-ceramide (25µM) for 24h in the presence of IGF-1. 
Proliferation was determined as described above.  In further studies, the cells were 
treated with C2-ceramide (25µM) in the presence of IGF-1 in the presence of 
AG1024, an IGF-1 and insulin receptor blocker, (10µM) (Sigma) for 24h (Lee et al. 
2005; Sutter et al. 2006).  The diluent for AG1024 was dimethylsulfoxide (final 
concentration 0.1%).  Control cultures received 0.1% dimethylsulfoxide only.  
Proliferation was determined as described above. The minimum concentration at 
which ceramide could inhibit IGF-1-induced proliferation in ATDC5 cells was 
examined using C2-ceramide concentrations between 10µM and 40µM at 5µM 
intervals using serum free medium.  
 
Western blotting analysis 
ATDC5 cells were treated with C2-ceramide (25µM) for 24h, and then either lysed 
immediately or stimulated with IGF-1 (100ng/ml) for 10 min and then lysed.  Cells 
were lysed in PhosphoSafe extraction buffer (Merck Biosciences Ltd, Nottingham, 
UK) containing “Complete” protease inhibitor cocktail (Roche, East Sussex, UK) 
according to manufacterer's instructions. Lysates (corresponding to 25µg protein) 
were run on 10% Bis-Tris gels (Invitrogen, Paisley, UK) and transferred onto a 
nitrocellulose membrane. The membranes were blocked with 5% non-fat dry milk in 
Tris-buffered saline/Tween-20 (TBST; 50mM Tris-HCl, 300mM NaCl, 0.1% Tween-
20, pH 7.6) at 4°C overnight with gentle shaking. The membranes were probed for 1 
hour at room temperature with primary antibodies (all 1:1000 dilution in 5% milk) 
against phospho-Akt (ser 473), total Akt, phospho-P44/42 Map Kinase (Thr202-
/Tyr204), total P44/42 Map Kinase, Phospho-SAPK/JNK (Thr183/Tyr185), total 
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SAPK/JNK, Phospho-p38 MAP Kinase (Thr180/Tyr182) and total p38 MAP Kinase 
(Cell Signaling Technology, Beverly, MA).  The blots were washed 4 × 15 min in 
TBST. The membranes were then incubated with anti-rabbit IgG-peroxidase (Cell 
Signalling Technology) for 1h (1:1000 dilution in 5% milk). The membranes were 
washed, as described above, and developed using the ECL-plus Western Blotting 
Detection System (Amersham Biosciences, Buckinghamshire, UK). 
 
Immunoprecipitation of IRS-1 
ATDC5 cells were treated with C2-ceramide (25µM) for 24h, and then stimulated 
with IGF-1 (100ng/ml) for 10 min.  Cells were then lysed in lysis buffer (150mM 
NaCl ; 10mM Tris.HCl pH 7.4 ; 0.5 % NP40 ; 1mM Sodium Vanadate; 0.5M  EDTA; 
0.1M PMSF; 4mg/l aprotinin. IRS-1 was immunoprecipitated by incubating cell 
lysates overnight at 4°C with 2 µg/ml of anti - IRS-1 antibody and 30µl of protein A-
Sepharose beads. Protein bound to the beads was washed four times with lysis buffer, 
and 10ul aliquots were run on 3-8% Tris-Acetate gels (Invitrogen) and transferred 
onto a nitrocellulose membrane. The membranes were blocked as described above, 
and then probed for 1 hour at room temperature with antiphosphotyrosine clone 4G10 
and total IRS-1 antibodies (Upstate, Lake Placid, New York, USA).  The blots were 
washed 4 × 15 min in TBST. The membranes were then incubated with anti-mouse 
IgG-peroxidase (Cell Signalling Technology) for 1h (1:1000 dilution in 5% milk). 
The membranes were washed and developed as described above. 
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Organ culture 
The middle three metatarsals were aseptically dissected from 19-day-old embryonic 
Swiss mice.  Bones were cultured at 37°C in a humidified atmosphere of 95% air / 5% 
CO2 in 24 well plates.  Each culture well contained 300µl of αMEM (Invitrogen) 
supplemented with 0.2% Bovine Serum Albumin, Fraction V (Sigma); 1mmol/l β-
glycerophosphate (Sigma); 0.05mg/ml L-ascorbic acid phosphate (Wako Pure 
Chemicals Ltd, Neuss, North Rhine-Westphalia, Germany); 0.05mg/ml gentamycin 
and 1.25ug/ml fungizone (Invitrogen) (Mushtaq et al. 2004).  C2-ceramide was added 
at a final concentration of 40, 30, 20 and 10µM for an 8 day period.  In further studies 
with IGF-1, C2-ceramide was added at a final concentration of 40µM for an 8 day 
period, in the presence of IGF-1 (100ng/ml). The minimum concentration at which 
ceramide could affect metatarsal growth was examined using C2-ceramide 
concentrations between 0µM and 40µM at 10µM intervals using serum free medium 
in the fetal metatarsal culture model. In all experiments, the medium was changed 
every second/third day. 
 
Morphometric analysis 
Digital images of the metatarsals were captured every second day of culture and 
viewed on a Nikon Eclipse TE3000 microscope (Nikon, Kingston upon Thames 
Surrey, UK), using a digital camera (DS Camera Head DS-5M; Nikon).  The total 
length of the bone through the centre of the mineralising zone was determined using 
image analysis software (DS Camera Control Unit DS-L1; Nikon).  All results are 
expressed as a percentage change from harvesting length, which was regarded as 
baseline. 
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Statistical analysis 
All experiments were performed at least twice.  General Linear Model analysis was 
used to assess the data.  All data are expressed as the mean +/- S.E.M. of six 
observations within each experiment.  Statistical analysis was performed using 
Minitab 14.  P<0.05 was considered to be significant.  
 
Results 
Ceramide generation following pro-inflammatory cytokine exposure. 
TNFα (10ng/ml) significantly reduced proliferation compared to control cells (Fig. 1; 
93%; P<0.001).  When added in the presence of TNFα, D609 (10µg/ml) significantly 
increased proliferation compared to cytokine treatment alone (Fig. 1; 927%; 
P<0.001).  D609 also significantly increased proliferation in control cells (Fig. 1; 
84%; P<0.001). 
 
Characterisation of the effect of C2-ceramide on ATDC5 cells. 
In the ATDC5 cells, 40µM C2-ceramide significantly reduced cell proliferation over a 
24h period (Fig. 2a), and this was confirmed when corrected for protein content (Fig. 
2b).  Following a 5 day exposure period, both 40 and 25µM C2-ceramide significantly 
reduced cell number (protein content) (Fig. 2c).  Apoptosis was also increased at both 
concentrations following exposure for 24h (Fig. 2d).  There was no significant 
alteration in C2-ceramide-induced mRNA expression of markers of chondrogenesis or 
differentiation (sox 9, collagen II aggrecan and collagen X) at all concentrations 
studied (Fig. 3). 
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IGF-1 studies  
The lowest concentration of C2-ceramide that inhibited ATDC5 cell proliferation 
following 18h serum deprivation was 25µM in the presence of IGF-1 (Fig. 4a).  Cells 
exposed to C2-ceramide (25µM) in the presence or absence of IGF-1 (100ng/ml) for 
24h indicated that IGF-1 alone significantly increased proliferation (Fig 4b; P<0.001).  
In the presence of IGF-1, C2-ceramide induced a 68% reduction in proliferation (Fig. 
4b; P<0.001).  However, in the absence of IGF-1, ceramide induced a comparable 
61% decrease (Fig. 4b; P<0.001). 
 
In the more physiological fetal metatarsal model, the lowest concentration of C2-
ceramide that significantly reduced fetal metatarsal growth was 40µM in the presence 
of IGF-1 (Fig. 5a; 62%; P<0.05). C2-ceramide (40µM) induced the same 31% 
reduction in metatarsal growth both in the presence and absence of IGF-1 (9d, 
100ng/ml) (Fig. 5b; both P<0.001).  
 
The effect of C2-ceramide on endogenous IGF-1 induced ATDC5 cell proliferation 
was examined, using AG1024, an IGF-1 and insulin receptor blocker (10µM) (Fig. 
4c).  In the absence of exogenous IGF-1, AG1024, an IGF-1 and insulin receptor 
blocker, reduced proliferation by 28% compared to control cells (P<0.001). C2-
ceramide (25µM) significantly reduced proliferation compared to AG1024 treatment 
(55%, P<0.001).  C2-ceramide and AG1024 in combination further reduced 
proliferation compared to C2-ceramide alone (46 %; P<0.01).  
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Cell signalling 
24h C2-ceramide exposure did not inhibit the IGF-1 induced phosphorylation of 
insulin receptor substrate –1 (IRS-1), Akt (protein kinase B) or P44/42 Map Kinase 
(Erk 1/2) (Fig. 6).  Further studies revealed that 24h C2-ceramide exposure did not 
alter Phospho-SAPK/JNK, Phospho-p38 MAP Kinase or phospho-P44/42 Map 
Kinase (Erk 1/2) activity (data not shown).  
Discussion 
Ceramide is an intracellular second messenger, whose signalling plays an important 
role in the regulation of cell proliferation, differentiation and survival (Kolesnick 
2002; Ruvolo 2002; Menaldino 2003). This is the first study to demonstrate that C2-
ceramide inhibits proliferation and induces apoptosis in growth plate chondrocytes. 
Ceramide has been shown to induce apoptosis in a wide range of different cell types, 
including pancreatic beta cells (Sjoholm et al. 2005), cardiomyocytes (de Vries et al. 
1997), astrocytes (Oh et al. 2006) and articular chondrocytes (Sabatini et al. 2000).  
An increase in ATDC5 proliferation was observed with TNFα exposure in the 
presence of D609, an inhibitor of ceramide generation.  This suggests that ceramide 
may mediate the effects of pro-inflammatory cytokines in growth plate chondrocytes.  
An increase in proliferation was also observed in presence of D609 in the control 
cells, demonstrating that growth plate chondrocytes have an endogenous production 
of ceramide.  Blocking this endogenous production therefore acts as an internal lid on 
proliferation.  
Standardisation of [3H] thymidine uptake with protein content confirms that an actual 
reduction in proliferation was observed following ceramide exposure, rather than 
solely a reduced uptake due in increased apoptosis and therefore fewer cells.  Both 
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TNFα and IL-1β exposure have also been reported to inhibit proliferation and induce 
apoptosis in ATDC5 cells (MacRae et al. 2006b), suggesting that ceramide may be 
acting as a second messenger.  Both IL-1B and TNFa have been shown to markedly 
reduce the mRNA expression of collagen II, collagen X and aggrecan (MacRae et al. 
2006b) but in our current study ceramide did not alter the mRNA expression of 
markers of chondrogenesis and differentiation (sox 9, collagen II, aggrecan and 
collagen X) suggesting that ceramide generation may be just one of many different 
pathways through which the pro-inflammatory cytokines act.    
 
Having established that C2-ceramide inhibits proliferation, and induces apoptosis, we 
went on to investigate whether these effects are mediated through inhibition of the 
IGF-1 signalling pathway, which is the major autocrine/paracrine regulator of bone 
growth (Loveridge et al. 1990). Strle et al. (2004) demonstrated that ceramide inhibits 
IGF-1 induced protein synthesis and differentiation in myoblasts.  However, it has 
also reported that ceramide can inhibit myoblast growth and differentiation in the 
absence of exogenous IGF-1 (Meadows et al. 2000; Strle et al. 2004).  It has been 
proposed that the discrepancies between these results can be attributed to the use of 
excessively high concentrations of C2-ceramide, and using cell culture media 
supplemented with low concentrations of serum (Strle et al. 2004).  In our hands, the 
lowest concentration of C2-ceramide that inhibited ATDC5 cell proliferation 
following 18h serum deprivation was 25µM in the presence of IGF-1, compared to 
40µM under standard culture conditions.  This indicates that the ATDC5 cells are 
more susceptible to the actions of ceramide when serum deprived, and under stress. 
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C2-ceramide induced a comparable reduction in ATDC5 proliferation and fetal 
metatarsal growth both in the absence and presence of exogenous IGF-1. Furthermore,  
In the presence of AG1024, an IGF-1 and insulin receptor blocker, ceramide was still 
able to inhibit proliferation.  
 
Cell signalling studies confirmed that ceramide did not inhibit the IGF-1 induced 
phosphorylation of IRS-1, or the major downstream pathways of IRS-1 - P44/42 Map 
Kinase and PI3 Kinase (as determined by Akt phosphorylation). Previous studies have 
reported that ceramide inhibits IGF-1 induced IRS-1 phosphorylation in certain cell 
types including myoblasts and hepatic cells (Kanety et al. 1996; Strle et al. 2004), but 
not in others, such as adipocytes (Summers et al. 1998) and motor neuron cells (Zhou 
et al. 1998).  Ceramide has been shown to inhibit IGF-1 induced Akt phosporlyation 
in other cell types, including kidney cells, fibroblasts and adipocytes (Meier et al. 
1998; Chen et al. 1999).  
Involvement of MAPK subfamilies (P44/42 Map Kinase, c-Jun N-terminal kinase 
(JNK), and p38 kinase) in ceramide-induced apoptosis have been reported in various 
cell types including astrocytes (Blazquez et al. 2000; Oh et al. 2006), neuronal cells 
(Verheij et al. 1996; Willaime et al. 2001; Willaime-Morawek et al. 2003),  lung 
cancer derived cells (Kurinna et al. 2004), vascular smooth muscle cells (Loidl et al. 
2004) .  The P44/42 Map Kinase pathway plays a major role in regulating cell growth, 
survival, and differentiation. In contrast, JNK and p38 pathways are activated in 
response to chemical and environmental stress (Xia et al. 1995; Cobb 1999). 
However, our studies showed that in growth plate chondrocytes, whilst ceramide 
induced apoptosis, the phosphorylation of P44/42 Map Kinase, JNK and p38 kinase 
was not altered. 
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Our previous studies have shown that IGF-1 plays a major role in promoting 
longitudinal growth in the mouse metatarsal model (Mushtaq et al. 2004). 
Furthermore the growth inhibitory effect of Dexamethasone was reversed in this 
model following exposure to IGF-1 (Mushtaq et al. 2004). However, the growth 
inhibitory effects of TNFa and IL1 are only partially reversed following treatment 
with IGF-1 (Martensson et al. 2004), suggesting that some of the effects of these 
proinflammatory cytokines may be IGF-1 independent. Furthermore, recombinant 
human growth hormone therapy in children with growth retardation and chronic 
inflammatory disease may result in a rise in IGF-1 and a cessation in further 
deterioration in growth (Davies et al. 1997; Bechtold et al. 2003). However, the 
failure to observe a clear normalisation of growth may be explained by the possibility 
that the growth retardation in these children may be due to a combination of a defect 
in growth regulatory pathways that are IGF-1 dependent and independent. 
In conclusion, we have reported for the first time in growth plate chondrocytes, a link 
between pro-inflammatory cytokines and ceramide generation, and an anti-
proliferative and pro-apoptotic effect of ceramide.  Interestingly, these effects appear 
to be IGF-1 independent.  Inflammatory cytokine induced generation of ceramide, and 
its subsequent actions on the growth plate, may be associated with the abnormal 
growth observed in children suffering from chronic inflammatory diseases. 
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